James Whitlock

Division Head

Hospital for Sick Children

Canada

Research Interests

Explore related searches

Professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

James Whitlock is the Division Head at The Hospital for Sick Children in Canada. His research focuses on pediatric oncology, particularly in areas including BRAF V600-mutant lesions, acute lymphoblastic leukemia, and innovative therapeutic approaches such as ALK inhibition and immunotherapy. He has contributed to several significant studies aimed at improving outcomes for pediatric patients with various hematological malignancies.

Articles (10)

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (7)

Linlea Armstrong

Clinical Associate Professor

The University of British Columbia

CANADA

View details

Birgit Geoerger

Université Paris-Saclay

FRANCE

View details

Benjamin Durham

Assistant Professor, Tenure-Track

Rutgers Cancer Institute of New Jersey

UNITED STATES

View details

Nabeel Yaseen

Professor

Northwestern University Feinberg School of Medicine

UNITED STATES

View details

Jennifer Picarsic

Associate Professor

Cincinnati Children's Hospital Medical Center

UNITED STATES

View details

Eric Bouffet

University of Toronto

CANADA

View details

Darren Hargrave

University College London

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

James Whitlock

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600–Mutant Low-Grade Glioma

Dabrafenib, alone or in combination with trametinib, in BRAF V600–mutated pediatric Langerhans cell histiocytosis

ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition

Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001).

Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes

Allogeneic Hematopoietic Stem Cell Transplantation for Children With Acute Lymphoblastic Leukemia: Shifting Indications in the Era of Immunotherapy.

Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433.

Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction.

First report of t(5;11) KMT2A-MAML1 fusion in de novo infant acute lymphoblastic leukemia.

Collaborators (7)

Linlea Armstrong

Birgit Geoerger

Benjamin Durham

Nabeel Yaseen

Jennifer Picarsic

Eric Bouffet

Darren Hargrave

Make your next move.